Will stock surge before Earnings results? KalVista Pharmaceuticals (NASDAQ:KALV)

Earnings results for KalVista Pharmaceuticals (NASDAQ:KALV)

KalVista Pharmaceuticals, Inc. is estimated to report earnings on 03/09/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.6. The reported EPS for the same quarter last year was $-0.52.

KalVista Pharmaceuticals last released its earnings data on December 9th, 2020. The specialty pharmaceutical company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.09. KalVista Pharmaceuticals has generated ($1.64) earnings per share over the last year. KalVista Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, March 9th, 2021 based off prior year’s report dates.

Analyst Opinion on KalVista Pharmaceuticals (NASDAQ:KALV)

6 Wall Street analysts have issued ratings and price targets for KalVista Pharmaceuticals in the last 12 months. Their average twelve-month price target is $50.17, predicting that the stock has a possible upside of 63.73%. The high price target for KALV is $61.00 and the low price target for KALV is $32.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of “Buy.”

KalVista Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $50.17, KalVista Pharmaceuticals has a forecasted upside of 63.7% from its current price of $30.64. KalVista Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Dividend Strength: KalVista Pharmaceuticals (NASDAQ:KALV)

KalVista Pharmaceuticals does not currently pay a dividend. KalVista Pharmaceuticals does not have a long track record of dividend growth.

Insiders buying/selling: KalVista Pharmaceuticals (NASDAQ:KALV)

In the past three months, KalVista Pharmaceuticals insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,835,025.00 in company stock. Only 18.00% of the stock of KalVista Pharmaceuticals is held by insiders. 90.19% of the stock of KalVista Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Earnings and Valuation of KalVista Pharmaceuticals (NASDAQ:KALV

Earnings for KalVista Pharmaceuticals are expected to decrease in the coming year, from ($2.67) to ($3.44) per share. The P/E ratio of KalVista Pharmaceuticals is -14.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of KalVista Pharmaceuticals is -14.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. KalVista Pharmaceuticals has a P/B Ratio of 6.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

More latest stories: here